Doris Helbig

University Hospital Cologne — Germany

Medicine · Health Sciences

18h-index1.0kcitations163works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(40), Vascular Tumors and Angiosarcomas(22), Cancer and Skin Lesions(21), Cutaneous Melanoma Detection and Management(19), Cutaneous lymphoproliferative disorders research(19)

Publications164 total

Histo-Miner: Deep learning based tissue features extraction pipeline from H&E whole slide images of cutaneous squamous cell carcinoma
PLoS Computational Biology·2026Open Access
Histo-Miner: Deep learning based tissue features extraction pipeline from H&E whole slide images of cutaneous squamous cell carcinoma
PLoS Computational Biology·2026Open Access
503 Impact of mitochondrial damage on dermal fibroblast function and fibrotic development
Journal of Investigative Dermatology·2025
Supplementary Table S10 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Data from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S11 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Figure S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Tables S6-S9 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Table S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Figure S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Supplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
2025Open Access
Multi-Omics Molecular Profiling Enables Rapid Diagnosis of Erythrodermic Skin Diseases
2025Open Access
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients
European Journal of Cancer·2025· 1 citedOpen Access
Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Clinical Cancer Research·2025
page 1 of 9Next →

Frequent Co-authors

Uwe Paasch(10), Cornelia Mauch(8), Alexander Quaas(8), Selma Ugurel(8), Stephan Grabbe(8), Mirjana Ziemer(7), Ulrike Leiter(6), Jochen Utikal(6), Alexander Kreuter(5), Sebastian Klein(5), Uwe Hillen(5), Stefan Eßer(5), Jan C. Simon(5), Edgar Dippel(4), Reinhard Buettner(4), Jürgen C. Becker(4), Reinhard Büttner(3), Marc Oliver Bodendorf(3), Michael Kendler(3), Jan C. Simon(3)